An Open-Label Study of the Improvements in Clinical Symptoms and Neurocognitive Functions in Korean Children and Adolescents with Attention-Deficit Hyperactivity Disorder after Treatment with Metadate CD.
- Author:
Hanik K YOO
1
;
Bongseog KIM
;
Yoo Sook JOUNG
;
Geon Ho BAHN
;
Dong Ho SONG
;
Dong Hyun AHN
;
Young Sik LEE
Author Information
1. Seoul Brain Research Institute, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
ADHD;
Metadate CD;
Effectiveness;
Safety;
Comprehensive Attention Test
- MeSH:
Adolescent;
Ambulatory Care Facilities;
Animals;
Anorexia;
Cats;
Child;
Corneal Dystrophies, Hereditary;
Headache;
Humans;
Korea;
Memory;
Memory, Short-Term;
Methylphenidate;
Nausea;
Reaction Time
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2011;22(4):253-261
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: This study aimed to investigate the efficacy and safety of Metadate CD (MCD) when given to Korean children and adolescents with attention-deficit hyperactivity disorder (ADHD). We also explored the effects of the drug on diverse neurocognitive functions. METHODS: Ninety-one subjects with ADHD (mean age 8.6+/-2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drug's effects. RESULTS: After 0.92+/-0.32mg/kg/day of MCD were administered for 57.4+/-7.6 days, there was a 48.5% reduction in the mean total ARS scores (p<.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p<.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p<.05). The forward memory span of the spatial working memory test scores increased (p<.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%). CONCLUSION: This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.
